Rizzo The Nihilizo

Friday, October 27, 2006

Opiate and (meth)Amphetamine Tolerances: Reduction, Prevention, Information:

We all know how much tolerance sucks; it will burn holes in your pockets, prevents you from getting as high as you used to, and increases the chance you're going to overdose. Well, I'm just here to let you know it doesn't have to be like that. There is hope to stop yourself from gaining tolerance, and to even completely reverse it to the point where you're getting as high as you did the first time. Do you remember the first time you got high on your opiate/opiod of choice, or the first time you got spun as fuck on meth/amps? It was fucking beautiful, huh?

NDMA antagonists have been shown to reduce tolerance to morphine:

Co-administration of dextromethorphan, memantine or MRZ 2/579 between tests 1 and 2 dose-dependently (5-10 mg/kg) inhibited the development of morphine tolerance.

Although this study shows DXM along with memantine stops a user from gaining morphine tolerance, there is some evidence that DXM alone can stop an opiate tolerance and maybe even reverse it. Also, even if DXM is not very powerful at directly reducing tolerance without another NMDA antagonist, it can certainly potentiate the effects of opiates, and reduces the negative effects of them:

Preclinical and double-blind single-dose placebo-controlled studies demonstrated that MorphiDex (MS:DM), a 1:1 ratio of morphine sulfate (MS) to dextromethorphan hydrobromide (DM), provides significantly greater analgesia than an equal dose of immediate release MS, with a faster onset, and a duration of > or = 8 h. The analgesic effect of MS:DM compared to MS was evaluated in 2 double-blind, multiple-dose studies in 321 patients with cancer and other chronic pain: a crossover study that consisted of two 2-wk periods and a 4-wk parallel study. As specified in the study protocols, patients took sufficient MS or MS:DM to achieve satisfactory pain control. In the crossover study, the MS:DM group required half as much morphine as the MS group to achieve satisfactory pain control (80 mg and 162 mg, respectively). The interval between doses and the time from the last dose of the day to the first dose of the next day were significantly longer for MS:DM compared to MS. In the parallel study, MS:DM also provided pain control at a significantly lower dose. After four weeks of treatment, the mean daily dose of MS increased, while there was little change in the MS:DM mean daily dose (P = 0.025) to maintain satisfactory pain control. More patients preferred MS:DM to run-in MS than preferred MS to run-in MS (P = 0.026). The addition of DM to MS did not increase the incidence of adverse events, which were those commonly associated with opioid use. These studies confirm that MS:DM provides satisfactory pain relief but at a significantly lower morphine daily dose.

From here.

Note that DXM is not the best choice for reducing tolerance, it is just the cheapest and most available. Do not think that a "stronger" dissociative like ketamine or PCP will work better, because it is likely that DXM's tolerance reducing ability is linked to the specific sigma receptors with which it is an agonist of. NMDA antagonists also reduce tolerance to amphetamine. It should be noted that some doses of NMDA antagonists will only stop tolerance, not reverse it:

A rat warm-water tail-withdrawal procedure was used to examine the effects of chronic administration of the competitive NMDA receptor antagonist LY235959 in morphine tolerant rats. Morphine dose-dependently increased tail-withdrawal latencies from 55 degree C water. When morphine (10 mg/kg) was administered twice-daily for 7 days, the morphine dose-effect curves shifted 0.3-0.5 log unit to the right. When morphine was administered for an additional 7 days, the morphine dose-effect curve shifted 0.4 log unit further to the right. Co-administration of LY235959 (1, 3, 10 mg/kg) along with morphine prevented the development of tolerance observed during the second week of chronic morphine administration. Although the highest dose of LY235959 (10 mg/kg) partially reversed tolerance in five of seven rats, tolerance was not reversed by lower doses of LY235959. These data suggest that NMDA receptor antagonists may effectively prevent the progressive development of morphine tolerance at doses that are not sufficient to reverse pre-established morphine tolerance.

From here.

Here's an extremely helpful thread from bluelight:

Amphetamine tolerance is caused by excess Ca++ influx through the NMDA receptor gated calcium channels on the outer membranes of the dopamine cells bodies in the ventral tegental area, one of two areas in the brain with concentrations of dopamine producing neurons.

As alluded to above, taking an appropriate NMDA (partial) antagonist will prevent the development of a tolerance for the effects of an amphetamine or amphetamine-like stimulant. Also, by preventing excess Ca++ influx into the neuron, an NMDA antagonist will prevent associated brain alterations and damage (excitotoxicity).

Studies have indicated that amphetamine tolerance is prevented by exogenous or endogenous agents that are able to inhibit excess Ca++ influx into the neuron through the gated calcium channels on the neuronal membrane that have NMDA subtype glutamate receptors .Glutamate , the body’s major excitatory neurotransmitter, opens the gated calcium ion channels upon attaching to the NMDA receptor. A number of other receptors are also expressed on these calcium channels, which, when stimulated, either facilitate or inhibit glutamate’s action.

It is also important that agents that inhibit calcium channel activity not also cause deficient Ca++ influx. For example, ketamine is a full NMDA receptor antagonist, that prevents excess Ca++ influx and amphetamine tolerance. But being a full NMDA antagonist, ketamine in excessive doses results in deficient Ca++ influx. This could be one of the reasons it leaves K-user in a state of disassociation.

So, basically you can stop amphetamine tolerance and even reduce it if you can stop the Ca++ influx. How can you do this? Quite easily, actually. From the same post that I quoted earlier:

Magnesium is also an NMDA antagonist. Most people are deficient in magnesium, and stress reduces magnesium levels. Whether or not one takes amphetamines, magnesium supplementation is very important for mood, general well-being and keeping stress levels under control. It is also important to take magnesium in efficient form, with adequate bioavailability. The best type is magnesium glycinate (chelated) with bioavailability at around 80%. Second best is magnesium carbonate with (I don't remember exactly) bioavailability at little above 30%. Supplemented magnesium should be at 500 mg/day level. Also there is a study which shows that children who use amphetamine-type stimulants have bad magnesium/calcium balance. Calcium levels stay the same with amphetamine usage, but magnesium levels drop.

There are a few theories regarding just how exactly NMDA antagonists are able to reduce tolerance. One of these ideas, regarding neuroplasticity , is the idea that NMDA receptors are responsible for tolerance, physical dependence, and sensitization, and so thusly NMDA antagonists are able to reduce and prevent tolerance:

RESULTS: The effects of NMDA receptor antagonists on the development of tolerance to opiate analgesia and the development of opiate physical dependence do not appear to be due to confounding behavioral effects produced by high doses of NMDA receptor antagonists, "side-effects" of a particular drug or drug class, blockade of associative learning processes, or state-dependency. Results on tolerance and sensitization to the locomotor effects of morphine are more mixed and controversial; however, there is evidence suggesting that NMDA receptor antagonists may inhibit these phenomena in a similar manner. CONCLUSIONS: NMDA receptor antagonists appear to inhibit the neural plasticity underlying some forms of opiate tolerance, sensitization and physical dependence, suggesting that NMDA receptors are involved in the development of these drug-induced changes in behavior. Further research will help to determine the neural mechanisms responsible for these phenomena, and the therapeutic potential for drugs acting on the NMDA receptor complex in the treatment of pain and addiction.

Taken from here.

For those of you in extreme pain daily, or just most of the time, I highly sympathize with you, as I have my own chronic pain problems. However, there is evidence to suggest that hyperalgesia is related to opiate tolerance, the idea of which will most likely not surprise some of you who are in pain and have a huge natural or perhaps "unnatural" opiate tolerance:

A model proposing that N-methyl-D-aspartate (NMDA) receptor and opioid receptor mechanisms overlap and interact within the same dorsal horn nociceptive neurons makes several predictions. First, hyperalgesia should be associated with opioid tolerance. Second, both hyperalgesia and tolerance to opioid-analgesia should be blocked by an NMDA-receptor antagonist. Results from our laboratory and others support these predictions and point to several clinical implications. One is that, in addition to preventing tolerance and dependence, combining NMDA-receptor antagonists with both opioid and nonopioid analgesics may increase their analgesic potency. Preclinical animal studies demonstrate these advantages and underscore the practicality of the combined administration of nontoxic NMDA-receptor antagonists with various types of analgesic drugs.

Taken from here.

This study is suggesting that NDMA antagonists are able to reduce and prevent tolerance because opiate receptors and NMDA receptors overlap in their mechanisms. If one has an idea of how NDMA receptors and opiate receptors work, this makes sense:

The signal from opioid receptor activation is transduced through ion channels for potassium, calcium, and enzyme systems in the cytosol and cell membrane (protein kinase C, adenylate cyclase, phospholipase A2, nitric oxide synthase, and possibly metabotropic glutamate receptors). Analgesia occurs as intracellular K+ increases, Ca++ decreases, and cyclic AMP (cAMP) decreases.

From here.

This is starting to make sense now, isn't it? There is further proof that opiate tolerance(and amphetamine tolerance as well) has something strongly to do with a Ca++ influx. This study suggests that nimodipine, a calcium channel blocker, can increase the analgesic effects of morphine and/or reduce tolerance:

The ability of nimodipine, a calcium-channel blocker, to enhance morphine analgesia and/or modify the development of tolerance was studied in patients with cancer pain who had needed successive increments of morphine for periods ranging from 21 to 780 days. Assessment of daily morphine consumption was the primary effect parameter. Nimodipine succeeded in reducing the daily dose of morphine in 16 of 23 patients (oral, n = 13; intrathecal, n = 3), and failed to modify it in 2 patients. Total oral daily dose was reduced by nimodipine (120 mg/day) from 282.6 +/- 47.7 mg to 158.7 +/- 26.2 mg (n = 15, P < n =" 3)" n =" 2).">

Specifically regarding amphetamines, amphetamines seem to throw off the magnesium-calcium ratio (the two are heavily related and are almost always absorbed together):

Dextroamphetamine can increase blood levels of magnesium, which causes significant lowering of the calcium to magnesium ratio in the blood. The change in this ratio may in part explain the effectiveness of stimulants like dextroamphetamine in hyperactive boys.

1 Another magnesium-amphetamine interaction involves supplements of magnesium hydroxide, which are known to cause retention of amphetamines in the body.

2 This could theoretically result in increased blood levels of these drugs. Finally, animal studies have suggested that magnesium supplements can increase learning and enhance the behavioral response to stimulants.

3 For these reasons, the use of magnesium along with amphetamines may enhance the effectiveness of these drugs in the treatment of ADD, but controlled studies of this possibility are needed.

References:

1. Schmidt ME, Kruesi MJ, Elia J, et al. Effect of dextroamphetamine and methylphenidate on calcium and magnesium concentration in hyperactive boys. Psychiatry Res 1994;54:199–210.

2. Hurwitz A. Antacid therapy and drug kinetics. Clin Pharmacokinet 1977;2:269–80.

3. Reviewed in Schmidt ME, Kruesi MJ, Elia J, et al. Effect of dextroamphetamine and methylphenidate on calcium and magnesium concentration in hyperactive boys. Psychiatry Res 1994;54:199–210.

In conclusion, while there are many theories regarding opiate/amphetamine tolerance and the relate to NMDA antagonists/Ca++ influx(et cetera), there is no concrete idea of the "why" or the "how". There are some basic ideas, but the for those of you not interested in the science of it all, and would rather just focus on the practical purposes, there is plenty of information on lowering and stopping tolerances. This is by no means meant to be an end-all post, but rather a general and basic primer for tolerance. There will be new and better information coming out all the time, so be sure to research this yourself.

Love,

-Rizzo

Labels: , , ,

Monday, October 9, 2006

Rizzo the mythbuster: Snorting benzos DOES work

In this post, I will not only conclusively show that administering benzodiazepines such as diazepam, lorazepam, and alprazoram work, but also work effectively.

It is a common perception among people who consider themselves knowledgeable about drugs that benzodiazepines such as diazepam can not be taken intranasal. The idea is that since benzos are not water soluble, they can not be absorbed in the mucous membranes in the nose, and thus only the drip (see: phlegm, a water based gel substance) gets you high, when it eventually reaches your stomach. This perception is fairly widespread, and so-called "n00bs" are lambasted for snorting any type of benzo outside of midazolam, a water soluble benzo. Considering there has been no scientific proof brought forth that to take benzos intranasal they have to be water soluble, I think it is safe to say for many people this is a matter of ego. Since there has been no scientific proof linking water solubility to benzo inefficiently in the nasal mucosa, I would like to point out that this should not be considered the de facto truth.

First of all, absorption of drugs commonly takes place in one of the many mucous membranes in the body. These places include the nose, the anus, the lips, under the tongue, the ears, and the genital area. (Wikipedia article on mucous membranes.) Drugs (among other things) are absorbed through the mucous membranes, into the local veins, into a main artery, and then soon after are to the brain. The advantage of taking drugs this way is that it bypasses first pass metabolism of the liver, which is extremely destructive to drugs, and it reaches the brain much quicker. This is why intranasal, sublingual, and anal administration is usually preferred to oral.

Bioavailability is a term used to describe the fraction of a dose that reaches the systemic circulation, or in more basic terms, how much of drug X that is actually reaching your brain. It is a basic description for determining how effective a certain method of administration is. One of the most important of these is lipid solubility. Lipids are a group of naturally occurring organic compounds that are related by their solubility in nonpolar organic solvents, and generally their insolubility in water. Although bioavailability also depends on a number of other factors, including but not limited to pH, molecular weight, etc, lipid solubility is the most important and the one I will be focusing on. Molecular weight does not matter that much seeing as how cocaine is a substance taken intranasal with a molecular weight of 303.353 g/mol, and diazepam has a molecular weight of 284.7 g/mol. The pH of a substance can be modified through different methods, and thus is not that important.

The intranasal bioavailability of diazepam in dogs is a whopping 80%, according to this study which states:

Mean bioavailability of BDZ following IN administration was 80 +/- 9%. CONCLUSIONS AND CLINICAL RELEVANCE: Diazepam is rapidly and efficiently absorbed following IN administration of the parenteral formulation. Plasma concentrations match or exceed the suggested therapeutic concentration (300 microg/L). Intranasal administration of diazepam may be useful for treatment of seizures in dogs by owners or when intravenous access is not readily available.

Obviously dogs are different than humans, but the nasal mucous membranes of mammals does not differ that much. Taken alone, this bit of information might not be conclusive, but there is more:

The purpose of this study was to evaluate the pharmacokinetic profile of intranasal lorazepam in comparison to currently established administration routes. Eleven healthy volunteers completed this randomized crossover study. On three occasions, each separated by a 1-week washout, subjects received a 2 mg dose of lorazepam via the intranasal, intravenous, or intramuscular route. Blood samples were collected serially from 0 to 36 hours. Noncompartmental methods were used to determine pharmacokinetic parameters. Lorazepam was well absorbed following intranasal administration with a mean (%CV) bioavailability of 77.7(11.1). Intranasal administration resulted in a faster absorption rate than intramuscular administration. Elimination profiles were comparable between all three routes. The concentration-time profile for intranasal delivery demonstrated evidence of a double peak in several subjects, suggesting partial oral absorption. Females were found to have significantly higher AUC values than males for all three delivery routes. Overall, this study demonstrated favorable pharmacokinetics of intranasal lorazepam in relation to standard administration methods. Intranasal delivery could provide an alternative, noninvasive delivery route for lorazepam.

Taken from this study. Not only is intranasal administration an efficient method, but my personal favorite method, sublingual, is also efficient:

Ten healthy volunteers received single 2-mg doses of lorazepam on five occasions in random sequence. Modes of administration were: A, intravenous injection; B, deltoid intramuscular injection; C, oral tablets in the fasting state; D, sublingual dosage of oral tablets in the fasting state; and E, sublingual dosage of specially formulated tablets in the fasting state. Kinetic variables were determined from multiple plasma lorazepam concentrations measured during 48 hr postdose. After intravenous lorazepam, mean (+/- SE) values were: elimination half-life (t 1/2 beta), 12.9 (+/- 0.8) hr; volume of distribution, 1.3 (+/- 0.07) liters/kg; total clearance, 1.21 (+/- 0.1) ml/min/kg. Absorption of intramuscular lorazepam was rapid. Peak plasma levels were reached at 1.15 hr after dosage, with absorption half-life averaging 14.2 (+/- 4.7) min. Absorption or oral and sublingual lorazepam tended to be less rapid than intramuscular injection, although differences were not significant. Times of peak concentration were 2.37, 2.35, and 2.25 hr postdose for trials C,D, and E, respectively; values of absorption half-life were 32.5, 28.5, and 28.7 min. Absolute systemic availability for trials B, C, D, and E averaged 95.9, 99.8, 94.1, and 98.2%, respectively; none of these differed significantly from 100%. Values of t1/2 beta were highly replicable within individuals regardless of the administration route. Thus, sublingual lorazepam is completely absorbed and is a suitable administration route in clinical practice.

From here. Here are some more studies that further prove my point:

Intranasal lorazepam is effective, safe, and provides a less invasive alternative to intramuscular paraldehyde in children with protracted convulsions. The ease of use of this drug makes it an attractive and preferable pre-hospital treatment option.

http://tinyurl.com/or2zo

Intranasal benzodiazepines produce rapid and effective sedation in canaries. Intranasal alpha(2) agonists produce sedation but not sustained recumbency. Specific antagonists are also effective when used by this route. Clinical relevance Intranasal sedative drug administration is an acceptable alternative method of drug delivery in canaries.

http://tinyurl.com/o56df

Not only is intranasal administration of benzodiazepines an efficient method in the medical community, it has been shown that it is widespread in the drug (ab)using community:

Two cases of intranasal benzodiazepine use are presented. The methods of preparation and administration of the powder and accounts of the pharmacological effects of the drugs used are described. The pattern of development and progress of the habit and its associated features are delineated. Snorting benzodiazepines appears to be more common than is currently appreciated, and the clinical complications and implications of this habit are discussed.
http://tinyurl.com/qtfaf

In conclusion, intranasal administration of benzodiazepines is not only an extremely efficient method of use, but is also prevalent in the recreational drug community. I have shown that drug absorption in the mucous membranes relies on lipid solubility, not water solubility, and that drugs that are lipid soluble are very often water insoluble. There is no scientific evidence whatsoever to give the impression that water-insoluble benzodiazepines can not be taken intranasal, and thus it is a 100% positive fact that it is a myth. Water insoluble benzos can be snorted, are snorted, and if one so desires, should be snorted.

Labels: , ,